Abstract
Colchicine is a tricyclic alkaloid extracted from the herbaceous plant Colchicum autumnale. Known since antiquity for its therapeutic efficacy in the treatment of gout, colchicine was reintroduced in 19th century pharmacopeia, thanks to the work of the French chemists and pharmacists Pierre-Joseph Pelletier (1788-1842) and Joseph Bienaimé Caventou (1795-1877) who in 1819, isolated a peculiar substance in the roots of Colchicum autumnale. In 1833, the substance was further analyzed by the German pharmacist and chemist Philipp Lorenz Geiger (1785-1836), who coined the name colchicine. In 1884, the French pharmacist Alfred Houde (1854-1919) produced for the first time pure crystallized colchicine in granules of 1milligram which is still sold under this trade name in several countries. In the last two centuries, colchicine's indications were furthermore expanded. From anti-gout drug during antiquity and a diuretic in 19th century, colchicine is currently administered in several affections such as Adamantiades-Behcet's disease, familial Mediterranean fever, pericarditis and atrial fibrillation.
Keywords: Colchicum, pierre-joseph pelletier, joseph bienaimé caventou, history of pharmacology, gout, atrial fibrillation.
Current Pharmaceutical Design
Title:Isolating Colchicine in 19th Century: An Old Drug Revisited
Volume: 24 Issue: 6
Author(s): Marianna Karamanou*, Gregory Tsoucalas, Konstantinos Pantos and George Androutsos
Affiliation:
- University Institute of History of Medicine and Public Health, Lausanne,Switzerland
Keywords: Colchicum, pierre-joseph pelletier, joseph bienaimé caventou, history of pharmacology, gout, atrial fibrillation.
Abstract: Colchicine is a tricyclic alkaloid extracted from the herbaceous plant Colchicum autumnale. Known since antiquity for its therapeutic efficacy in the treatment of gout, colchicine was reintroduced in 19th century pharmacopeia, thanks to the work of the French chemists and pharmacists Pierre-Joseph Pelletier (1788-1842) and Joseph Bienaimé Caventou (1795-1877) who in 1819, isolated a peculiar substance in the roots of Colchicum autumnale. In 1833, the substance was further analyzed by the German pharmacist and chemist Philipp Lorenz Geiger (1785-1836), who coined the name colchicine. In 1884, the French pharmacist Alfred Houde (1854-1919) produced for the first time pure crystallized colchicine in granules of 1milligram which is still sold under this trade name in several countries. In the last two centuries, colchicine's indications were furthermore expanded. From anti-gout drug during antiquity and a diuretic in 19th century, colchicine is currently administered in several affections such as Adamantiades-Behcet's disease, familial Mediterranean fever, pericarditis and atrial fibrillation.
Export Options
About this article
Cite this article as:
Karamanou Marianna*, Tsoucalas Gregory, Pantos Konstantinos and Androutsos George, Isolating Colchicine in 19th Century: An Old Drug Revisited, Current Pharmaceutical Design 2018; 24 (6) . https://dx.doi.org/10.2174/1381612824666180115105850
DOI https://dx.doi.org/10.2174/1381612824666180115105850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Kingella kingae: A Pediatric Pathogen of Increasing Importance
Current Pediatric Reviews Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Bacteremic Streptococcus pneumoniae in Community-Acquired Pneumonia: An Update
Current Respiratory Medicine Reviews Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets COVID-19 Vaccination in Children: An Open Question
Current Pediatric Reviews Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews The Use of Colchicine in Respiratory Diseases
Current Respiratory Medicine Reviews Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Pulmonary Involvement in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy Chronic Streptococcal and Non-Streptococcal Pharyngitis
Infectious Disorders - Drug Targets Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Forceps: Still an Option?
Current Women`s Health Reviews Transitional Connective Tissue Diseases: Description of Four Cases
Current Rheumatology Reviews